Clinical development of atypical antipsychotics: Research design and evaluation

Herbert Y. Meltzer*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations

Abstract

Clinical trials support the efficacy and safety of new drags on the market. They provide the United States Food and Drug Administration with the information needed to approve an Investigational New Drug application and are the basis for package inserts provided by the manufacturers that guide clinicians in the use of a new drug. Because clinical trials are vital to the effective and safe use of new drugs, it is important to understand who participates in them, what questions are answered by clinical trials, and what questions are raised. The reader who asks the proper questions about issues such as methodology, affiliations of the investigators; statistical analyses performed, location of study centers, and study populations will derive the most information from the report of a clinical trial.

Original languageEnglish (US)
Pages (from-to)10-16
Number of pages7
JournalJournal of Clinical Psychiatry
Volume59
Issue numberSUPPL. 12
StatePublished - 1998

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Clinical development of atypical antipsychotics: Research design and evaluation'. Together they form a unique fingerprint.

Cite this